Shanghai Golden Leaf Med Tech

Shanghai Golden Leaf Med Tech is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics. The company's primary focus is on targeting the ubiquitin-proteasome system (UPS) to treat various forms of cancer. Its lead candidate, GL-001, is a potent and selective inhibitor of Ubiquitin-specific protease 7 (USP7), currently undergoing clinical evaluation for solid tumors and hematological malignancies. By leveraging its expertise in medicinal chemistry and oncology biology, the company aims to address significant unmet medical needs in the global oncology market.